Zhang Y et al. gave an interesting indication about the role of PD-L1 (programmed cell death ligand 1) promoter aberrant methylation in mediating the mechanisms of resistance to the anti-PD1 treatment in EGFR mutated NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.